JNJosephine H. Naish

Josephine H. Naish

*This is an algorithmically generated author record based on publicly available information.

Josephine H. Naish has a total of 267 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Trientine for hypertrophic cardiomyopathy: a phase 2 trial.

    by John P Farrant, Susanna Dodd, Anna Rosala-Hallas, Carly Vaughan, Catherine Spowart, Emma Bedson, Dannii Clayton, Anna B Reid, Clifford J Garratt, Betty Raman, et al.

    Pathophysiological features of hypertrophic cardiomyopathy include left ventricular hypertrophy, myocardial fibrosis, and myocardial energy deficiency. Depletion of cardiomyocyte copper I ions leads to impaired mitochondrial function, a state associated with left ventricular hypertrophy. Unbound or loosely bound copper II ions activate profibrotic pathways. Trientine dihydrochloride improves intracellular copper I ion trafficking and availability, and chelates copper II ions. In preclinical studies, trientine improved myocardial mitochondrial function and reduced left ventricular hypertrophy and fibrosis. The efficacy and safety of trientine in persons with hypertrophic cardiomyopathy are unknown. In this multicentre, placebo-controlled phase 2 trial, adults with hypertrophic cardiomyopathy, a left ventricular wall thickness of 15 mm or greater, and who were in New York Heart Association class I to III were randomly assigned to receive trientine 400 mg twice daily or placebo for 52 weeks. Patients with any left ventricular outflow tract (LVOT) gradient were eligible. The primary endpoint was the change in left ventricular mass indexed to body surface area measured using cardiovascular magnetic resonance. A total of 154 patients underwent randomization. The mean age was 53.4 years, median maximum left ventricular wall thickness was 20.0 mm, median maximum LVOT gradient was 6.0 mmHg, 18.6% of patients had a resting LVOT gradient ≥30 mmHg, and 61.7% were in New York Heart Association class I. At 52 weeks, the mean change in the left ventricular mass indexed to body surface area was -4.4 ± 7.7 g/m2 in the trientine group and -1.5 ± 6.1 g/m2 in the placebo group (between-group difference -3.2 g/m2; 95% confidence interval -5.6 to -0.8; P = .009). The efficacy of trientine increased at higher levels of baseline left ventricular mass (baseline left ventricular mass indexed to body surface area by treatment allocation interaction P = .015). The effect of trientine was mediated via a reduction in myocardial cellular mass (average causal mediated effect -3.9 g/m2; 95% confidence interval -6.8 to -0.9). The incidence of adverse events was similar in the two groups. Among patients with hypertrophic cardiomyopathy, treatment with trientine resulted in a significantly greater reduction in left ventricular mass indexed to body surface area than placebo. (Funded by NIHR; TEMPEST ClinicalTrials.gov number, NCT04706429).


  • Open Access

    Determinants of myocardial fibrosis in patients with immune-mediated inflammatory diseases

    by Nicholas Black, Joshua Bradley, Fardad Soltani, John P. Farrant, Josephine H. Naish, Matthias Schmitt, Maya H. Buch, Christopher A. Miller

    Background: Myocardial fibrosis is an important adverse prognostic marker, however; determinants of myocardial fibrosis in immune-mediated inflammatory diseases (IMIDs) remain poorly defined. We aimed to identify determinants of myocardial fibrosis in patients with IMIDs, as measured by cardiovascular magnetic resonance (CMR) extracellular volume (ECV). Methods: Cross-sectional study of 116 patients with IMIDs undergoing clinical CMR at Manchester University NHS Foundation Trust. IMIDs included rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis (SSc), ankylosing spondylitis, psoriatic arthritis and vasculitis. CMR included pre- and post-contrast T1 mapping to measure myocardial ECV, with same day blood sampling. Determinants of ECV were investigated with univariable and multivariable linear regression. Results: ECV varied significantly according to IMID diagnosis (ANOVA F statistic 2.80, P = 0.015); ECV was higher in patients with SSc compared to other IMIDs. Major determinants of ECV as a continuous variable were SSc, smoking and body mass index (BMI); regression coefficients 3.33 (95% confidence interval 0.82–5.84), 3.08 (0.73–5.43), and − 0.19 (-0.29 – -0.09) respectively, P < 0.01 (SSc, smoking and lower BMI were associated with increased ECV). Approximately a quarter of the variability in ECV could be explained by these predictors (optimism adjusted R 2 0.265). Conclusion: SSc is associated with a higher burden of myocardial fibrosis compared to other IMIDs. In patients with IMIDs, independent determinants of myocardial fibrosis were presence of SSc, smoking and BMI. Importantly, participants underwent CMR for clinical indications and may not be representative of IMID populations in the community.


  • Open Access

    Comparison of 2D and 3D oxygen-enhanced MRI of the placenta

    by Penny L Hubbard Cristinacce, Minal Patel, Alexander Oh, Josephine H Naish, Edward D Johnstone, Emma Ingram

    Oxygen-Enhanced Magnetic Resonance Imaging (OE-MRI) of the human placenta is potentially a sensitive marker of in vivo oxygenation. This methodological study shows that full coverage of the placenta is possible using 3D mapping of the change in longitudinal relaxation rate (ΔR1), in a group of healthy pregnant subjects breathing elevated levels of oxygen. Twelve pregnant subjects underwent a comparison of 2D and 3D OE-MRI. ΔR1 was mapped for a single 2D slice (ss-2D), a single matched-slice from the 3D volume (ss-3D) and the full 3D volume (vol-3D). The group-average median ΔR1 values for ss-3D (0.023 s-1) and vol-3D (0.022 s-1) do not differ significantly from ss-2D (0.020 s-1), when compared using a two-tailed paired t-test (ss-3D (p = 0.58) and vol-3D (p = 0.70)). However, median baseline T1 (T1b) for ss-2D was higher (1603 ms) than T1b for ss-3D (1540 ms, p = 0.07) and significantly higher than vol-3D (1515 ms, p = 0.02), when compared using a two-tailed paired t-test. In contrast with previous studies, no correlation of median ΔR1 with gestation age at scan for the normal group (N = 10) was observed for ss-2D, likely due to the smaller gestational range. Full volume OE-MRI maps reveal sensitivity to changes in ΔR1, with some participants showing an enhanced gradient in the intermediate space between the fetal and maternal sides of the placenta in the 3D data. This study shows that it is feasible to acquire whole placental volume OE-MRI data in women with healthy pregnancy.


  • Advances in COPD imaging using CT and MRI: linkage with lung physiology and clinical outcomes

    by Amany F. Elbehairy, Helen Marshall, Josephine H. Naish, Jim M. Wild, Grace Parraga, Alexander Horsley, Jørgen Vestbo

    Recent years have witnessed major advances in lung imaging in patients with COPD. These include significant refinements in images obtained by computed tomography (CT) scans together with the introduction of new techniques and software that aim for obtaining the best image whilst using the lowest possible radiation dose. Magnetic resonance imaging (MRI) has also emerged as a useful radiation-free tool in assessing structural and more importantly functional derangements in patients with well-established COPD and smokers without COPD, even before the existence of overt changes in resting physiological lung function tests. Together, CT and MRI now allow objective quantification and assessment of structural changes within the airways, lung parenchyma and pulmonary vessels. Furthermore, CT and MRI can now provide objective assessments of regional lung ventilation and perfusion, and multinuclear MRI provides further insight into gas exchange; this can help in structured decisions regarding treatment plans. These advances in chest imaging techniques have brought new insights into our understanding of disease pathophysiology and characterising different disease phenotypes. The present review discusses, in detail, the advances in lung imaging in patients with COPD and how structural and functional imaging are linked with common resting physiological tests and important clinical outcomes.


  • Open Access

    Feasibility of dynamic T2*‐based oxygen‐enhanced lung MRI at 3T

    by Mina Kim, Josephine H. Naish, Sarah H. Needleman, Marta Tibiletti, Yohn Taylor, James P. B. O'COnnor, Geoff J. M. Parker

    Purpose: To demonstrate proof‐of‐concept of a T2*‐sensitized oxygen‐enhanced MRI (OE‐MRI) method at 3T by assessing signal characteristics, repeatability, and reproducibility of dynamic lung OE‐MRI metrics in healthy volunteers.Methods: We performed sequence‐specific simulations for protocol optimisation and acquired free‐breathing OE‐MRI data from 16 healthy subjects using a dual‐echo RF‐spoiled gradient echo approach at 3T across two institutions. Non‐linear registration and tissue density correction were applied. Derived metrics included percent signal enhancement (PSE), ∆R2* and wash‐in time normalized for breathing rate (τ‐nBR). Inter‐scanner reproducibility and intra‐scanner repeatability were evaluated using intra‐class correlation coefficient (ICC), repeatability coefficient, reproducibility coefficient, and Bland–Altman analysis.Results: Simulations and experimental data show negative contrast upon oxygen inhalation, due to substantial dominance of ∆R2* at TE > 0.2 ms. Density correction improved signal fluctuations. Density‐corrected mean PSE values, aligned with simulations, display TE‐dependence, and an anterior‐to‐posterior PSE reduction trend at TE1. ∆R2* maps exhibit spatial heterogeneity in oxygen delivery, featuring anterior‐to‐posterior R2* increase. Mean T2* values across 32 scans were 0.68 and 0.62 ms for pre‐ and post‐O2 inhalation, respectively. Excellent or good agreement emerged from all intra‐, inter‐scanner and inter‐rater variability tests for PSE and ∆R2*. However, ICC values for τ‐nBR demonstrated limited agreement between repeated measures.Conclusion: Our results demonstrate the feasibility of a T2*‐weighted method utilizing a dual‐echo RF‐spoiled gradient echo approach, simultaneously capturing PSE, ∆R2* changes, and oxygen wash‐in during free‐breathing. The excellent or good repeatability and reproducibility on intra‐ and inter‐scanner PSE and ∆R2* suggest potential utility in multi‐center clinical applications.


  • Open Access

    Independent component analysis (ICA) applied to dynamic oxygen‐enhanced MRI (OE‐MRI) for robust functional lung imaging at 3 T

    by Sarah H. Needleman, Mina Kim, Jamie R. McClelland, Josephine H. Naish, Marta Tibiletti, James P. B. O'COnnor, Geoff J. M. Parker

    Purpose: Dynamic lung oxygen‐enhanced MRI (OE‐MRI) is challenging due to the presence of confounding signals and poor signal‐to‐noise ratio, particularly at 3 T. We have created a robust pipeline utilizing independent component analysis (ICA) to automatically extract the oxygen‐induced signal change from confounding factors to improve the accuracy and sensitivity of lung OE‐MRI.Methods: Dynamic OE‐MRI was performed on healthy participants using a dual‐echo multi‐slice spoiled gradient echo sequence at 3 T and cyclical gas delivery. ICA was applied to each echo within a thoracic mask. The ICA component relating to the oxygen‐enhancement signal was automatically identified using correlation analysis. The oxygen‐enhancement component was reconstructed, and the percentage signal enhancement (PSE) was calculated. The lung PSE of current smokers was compared with nonsmokers; scan–rescan repeatability, ICA pipeline repeatability, and reproducibility between two vendors were assessed.Results: ICA successfully extracted a consistent oxygen‐enhancement component for all participants. Lung tissue and oxygenated blood displayed the opposite oxygen‐induced signal enhancements. A significant difference in PSE was observed between the lungs of current smokers and nonsmokers. The scan–rescan repeatability and the ICA pipeline repeatability were good.Conclusion: The developed pipeline demonstrated sensitivity to the signal enhancements of the lung tissue and oxygenated blood at 3 T. The difference in lung PSE between current smokers and nonsmokers indicates a likely sensitivity to lung function alterations that may be seen in mild pathology, supporting future use of our methods in patient studies.


  • Open Access

    Independent component analysis (ICA) applied to dynamic oxygen-enhanced MRI (OE-MRI) for robust functional lung imaging at 3 T

    by Sarah H. Needleman, Mina Kim, Jamie R. McClelland, Josephine H. Naish, Marta Tibiletti, James P. B. O’connor, Geoff J. M. Parker

    Purpose: Dynamic lung oxygen-enhanced MRI (OE-MRI) is challenging due to the presence of confounding signals and poor signal-to-noise ratio, particularly at 3 T. We have created a robust pipeline utilizing independent component analysis (ICA) to automatically extract the oxygen-induced signal change from confounding factors to improve the accuracy and sensitivity of lung OE-MRI. Methods: Dynamic OE-MRI was performed on healthy participants using a dual-echo multi- slice spoiled gradient echo sequence at 3 T and cyclical gas delivery. ICA was applied to each echo within a thoracic mask. The ICA component relating to the oxygen-enhancement signal was automatically identified using correlation analysis. The oxygen-enhancement component was reconstructed, and the percentage signal enhancement (PSE) was calculated. The lung PSE of current smokers was compared with non-smokers; scan-rescan repeatability, ICA pipeline repeatability, and reproducibility between two vendors, were assessed. Results: ICA successfully extracted a consistent oxygen-enhancement component for all participants. Lung tissue and oxygenated blood displayed opposite oxygen-induced signal enhancements. A significant difference in PSE was observed between the lungs of current smokers and non-smokers. The scan-rescan repeatability, and the ICA pipeline repeatability, were good. Conclusion: The developed pipeline demonstrated sensitivity to the signal enhancements of the lung tissue and oxygenated blood at 3 T. The difference in lung PSE between current smokers and non-smokers indicates a likely sensitivity to lung function alterations that may be seen in mild pathology, supporting future use of our methods in patient studies.

  • Open Access

    Rationale and design of a randomised trial of trientine in patients with hypertrophic cardiomyopathy

    by John Farrant, Susanna Dodd, Carly Vaughan, Anna Reid, Matthias Schmitt, Clifford Garratt, Mohammed Akhtar, Masliza Mahmod, Stefan Neubauer, Robert M Cooper, et al.

    Aims Hypertrophic cardiomyopathy (HCM) is characterised by left ventricular hypertrophy (LVH), myocardial fibrosis, enhanced oxidative stress and energy depletion. Unbound/loosely bound tissue copper II ions are powerful catalysts of oxidative stress and inhibitors of antioxidants. Trientine is a highly selective copper II chelator. In preclinical and clinical studies in diabetes, trientine is associated with reduced LVH and fibrosis, and improved mitochondrial function and energy metabolism. Trientine was associated with improvements in cardiac structure and function in an open-label study in patients with HCM. Methods The Efficacy and Mechanism of Trientine in Patients with Hypertrophic Cardiomyopathy (TEMPEST) trial is a multicentre, double-blind, parallel group, 1:1 randomised, placebo-controlled phase II trial designed to evaluate the efficacy and mechanism of action of trientine in patients with HCM. Patients with a diagnosis of HCM according to the European Society of Cardiology Guidelines and in New York Heart Association classes I–III are randomised to trientine or matching placebo for 52 weeks. Primary outcome is change in left ventricular (LV) mass indexed to body surface area, measured using cardiovascular magnetic resonance. Secondary efficacy objectives will determine whether trientine improves exercise capacity, reduces arrhythmia burden, reduces cardiomyocyte injury, improves LV and atrial function, and reduces LV outflow tract gradient. Mechanistic objectives will determine whether the effects are mediated by cellular or extracellular mass regression and improved myocardial energetics. Conclusion TEMPEST will determine the efficacy and mechanism of action of trientine in patients with HCM. Trial registration numbers NCT04706429 and ISRCTN57145331.


  • Open Access

    Comparison of 2D and 3D oxygen-enhanced MRI of the placenta

    by Penny L. Hubbard Cristinacce, Minal Patel, Alexander Oh, Josephine H. Naish, Edward D. Johnstone, Emma Ingram

    Oxygen-Enhanced Magnetic Resonance Imaging (OE-MRI) of the human placenta is potentially a sensitive marker of in vivo oxygenation. This methodological study shows that full coverage of the placenta is possible using 3D mapping of the change in longitudinal relaxation rate (ΔR 1 ), in a group of healthy pregnant subjects breathing elevated levels of oxygen. Twelve pregnant subjects underwent a comparison of 2D and 3D OE-MRI. ΔR 1 was mapped for a single 2D slice (ss-2D), a single matched-slice from the 3D volume (ss-3D) and the full 3D volume (vol-3D). The group-average median ΔR 1 values for ss-3D (0.023 s -1 ) and vol-3D (0.022 s -1 ) do not differ significantly from ss-2D (0.020 s -1 ), when compared using a two-tailed paired t-test (ss-3D (p = 0.58) and vol-3D (p = 0.70)). However, median baseline T 1 (T 1b ) for ss-2D was higher (1603 ms) than T 1b for ss-3D (1540 ms, p=0.07) and significantly higher than vol-3D (1515 ms, p = 0.02), when compared using a two-tailed paired t-test. In contrast with previous studies, no correlation of median ΔR 1 with gestation age at scan for the normal group (N = 10) was observed for ss-2D, likely due to the smaller gestational range. Full volume OE-MRI maps reveal sensitivity to changes in ΔR 1 , with some participants showing an enhanced gradient in the intermediate space between the fetal and maternal sides of the placenta in the 3D data. This study shows that it is feasible to acquire whole placental volume OE-MRI data on a Philips 1.5 T MRI scanner. Further work is necessary to implement this increased coverage on the scanners of other vendors.

  • Open Access

    Acute and Chronic Cardiopulmonary Effects of High Dose Interleukin-2 Therapy: An Observational Magnetic Resonance Imaging Study

    by Jakub Lagan, Josephine H. Naish, Christien Fortune, Christopher Campbell, Shien Chow, Manon Pillai, Joshua Bradley, Lenin Francis, David Clark, Anita Macnab, et al.

    High dose interleukin-2 (IL-2) is known to be associated with cardiopulmonary toxicity. The goal of this study was to evaluate the effects of high dose IL-2 therapy on cardiopulmonary structure and function. Combined cardiopulmonary magnetic resonance imaging (MRI) was performed in 7 patients in the acute period following IL-2 therapy and repeated in 4 patients in the chronic period. Comparison was made to 10 healthy volunteers. IL-2 therapy was associated with myocardial and pulmonary capillary leak, tissue oedema and cardiomyocyte injury, which resulted in acute significant left ventricular (LV) dilatation, a reduction in LV ejection fraction (EF), an increase in LV mass and a prolongation of QT interval. The acute effects occurred irrespective of symptoms. In the chronic period many of the effects resolved, but LV hypertrophy ensued, driven by focal replacement and diffuse interstitial myocardial fibrosis and increased cardiomyocyte mass. In conclusion, IL-2 therapy is ubiquitously associated with acute cardiopulmonary inflammation, irrespective of symptoms, which leads to acute LV dilatation and dysfunction, increased LV mass and QT interval prolongation. Most of these effects are reversible but IL-2 therapy is associated with chronic LV hypertrophy, driven by interstitial myocardial fibrosis and increased cardiomyocyte mass. The findings have important implications for the monitoring and long term impact of newer immunotherapies. Future studies are needed to improve risk stratification and develop cardiopulmonary-protective strategies.